Drug intelligence / Profile preview

Baiguo Wendan Decoction

Development stage: Preclinical
Lead developer: Heilongjiang University of Chinese Medicine
Administration: Oral

Overview

Baiguo Wendan Decoction is a Traditional Chinese Medicine (TCM) herbal formulation currently under investigation for its therapeutic effects on bronchial asthma in children. It is described as a self-formulated prescription, suggesting a specific or customized blend of traditional herbs. The ongoing clinical trial aims to explore its impact on asthma, particularly focusing on mechanisms related to the elimination of pathogens through purgation and diuresis, and its influence on intestinal microecology.

Targets

VEGFA (Vascular endothelial growth factor A)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)ESR1 (ERα)EGFR T790M (Epidermal growth factor receptor T790M mutant)IL-6 (Interleukin 6)CASP3 (Caspase-3)MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on Baiguo Wendan Decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baiguo Wendan Decoction.

Explore the full profile